Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Myovant Sciences Shares Rise on NDA Filing for Uterine Fibroid Combination Therapy Drug

Shares of Myovant Sciences traded 40% higher after the company reported that it has submitted a New Drug Application to the FDA for once-daily relugolix combination tablet for the treatment of women with uterine fibroids. Healthcare company Myovant Sciences Ltd. (...
Streetwise Reports | June 2, 2020 |

MyoKardia Shares Get a Jolt from Positive Phase 3 HCM Clinical Trial Results

Shares of MyoKardia traded 60% higher, setting a new 52-week high price, after the company reported that it met all primary and secondary endpoints in the Phase 3 EXPLORER study of mavacamten in treatment of obstructive hypertrophic cardiomyopathy. Clinical-...
Streetwise Reports | May 12, 2020 |

The Revolutionary Co. That’s Breaking Through the Blood Brain Barrier

(Click image to play video) Delivery of therapeutics across the blood-brain barrier (BBB) and into the brain has been the single greatest challenge to treating hundreds of common and rare neurological diseases, including brain cancers, neurodegenerative diseases...
Dave Jackson | December 1, 2020 |

Building a Better Covid-19 Antibody Test

ProMIS is harnessing its unique technology platform to develop a more error-free antibody test. Testing has been an Achilles heel of the coronavirus pandemic, but ProMIS Neurosciences Inc. (PMN:TSX; ARFXF:OTCQB) has partnered with Dr. Hans Frykman and the ...
Streetwise Reports | May 7, 2020 |

A ‘Barrier’ to Better Health

(Click image to play podcast) The blood-brain barrier plays an essential role in protecting the brain from blood-borne disease. But is also one of medicine’s great paradoxes – a system designed to protect the most sensitive region of the body bu...
Dave Jackson | September 29, 2020 |

Desert Gold, dynaCERT, Valeo Pharma - good news and the right time

Investors and speculators have a common interest: they want to make money. While investors usually plan for a longer time frame, speculators often just wait for the next good company news, then exit and move on. Listed companies that are the focus of attention and show a certa...
Mario Hose | September 3, 2020 |

Q&A with Cerro de Pasco Resources: Newly appointed CTO on the value of sustainable mining

If the World Economic Forum is any authority on the subject, the mining and metals sector – in its inherent connection to almost all industry value chains – “is an integral part of any foreseeable economy and society.” To that end, and with an ever-growi...
Oliver Gray | July 9, 2020 |

Dermira's Phase 2b Atopic Dermatitis Trial Results Send Shares 25% Higher

Dermira shares traded higher today after the firm released positive data from its phase 2b study of lebrikizumab in patients with atopic dermatitis at the Las Vegas Fall Clinical Dermatology Conference. Yesterday afternoon, Dermira Inc. (DERM:NASDAQ) , a biopharmaceu...
Streetwise Reports | October 21, 2019 |

Clinical Program Started for Agitation with Schizophrenia, Bipolar Disorder

The design of and an opinion on the included studies are provided in an H.C. Wainwright & Co. report. In a Dec. 30 research note, H.C. Wainwright & Co. analyst Ram Selvaraju reported that BioXcel Therapeutics Inc. (BTAI:NASDAQ) launched its pivotal trial program for...
Streetwise Reports | January 6, 2020 |

InMed Shares Trade Up 25% After Becoming First to Advance Cannabinol into Clinical Trials

InMed Pharmaceuticals shares traded 25% higher after reporting that it is the first to advance cannabinol into therapeutic clinical trials. Vancouver-based clinical stage biopharmaceutical company InMed Pharmaceuticals Inc. (IN:TSX; IMLFF:OTCQX) , which is engaged in...
Streetwise Reports | January 21, 2020 |
1 2 3 4 5 6 7 8 9 10 ...